Could a Routine Blood Draw Replace Your Next Colonoscopy?

A Simple Blood Draw for Cancer Screening: What You Need to Know About the FDA-Approved SimpleScreen™ CRC

Preventive health care just took a massive step forward. On July 27, 2026, the U.S. Food and Drug Administration (FDA) approved SimpleScreen™ CRC, a novel blood-based test designed to screen for colorectal cancer in adults aged 45 and older who are at average risk.

Developed by biotechnology firm Freenome and commercialized nationwide in partnership with Abbott, this new tool allows doctors to check for colorectal cancer through a simple, routine blood sample—no uncomfortable prep drinks or stool collection kits required.

For millions of adults who have put off life-saving screenings due to fear or inconvenience, this approval changes everything.

The 60-Million-Person Screening Problem

Colorectal cancer is the second leading cause of cancer-related deaths in the United States, yet it is also one of the most preventable and treatable forms of cancer when caught early.

Despite clear guidelines recommending that adults begin screening at age 45, an estimated 60 million Americans are currently overdue for their screening. The reasons are familiar:

• The invasive nature and multi-day preparation needed for colonoscopies.
• The mess and inconvenience of home stool collection tests.
• Busy schedules that make taking time off work for a procedure difficult.

Because the most effective screening test is always the one that actually gets completed, having a quick, non-invasive option integrated directly into routine annual checkups removes the primary barriers holding people back.

How SimpleScreen™ CRC Works

When cancer or precancerous cells exist in the body, they shed microscopic fragments of DNA into the bloodstream, known as cell-free DNA (cfDNA).

SimpleScreen™ CRC uses advanced artificial intelligence and machine learning models to analyze subtle molecular patterns—specifically genomic methylation signals—within these blood samples to spot early warning signs of cancer.

What the Clinical Data Shows

The FDA approval was backed by data from the PREEMPT CRC study, the largest clinical trial ever conducted for a blood-based colorectal cancer test, enrolling over 48,000 participants across more than 200 health centers:

• 81.1% Sensitivity for Colorectal Cancer: The test successfully identified more than 8 out of 10 cancer cases.
• 90.4% Specificity: It accurately ruled out cancer or advanced precancerous growth in 9 out of 10 people who were cancer-free.
• Strong Early Detection in Adults 45–49: In younger adults—a demographic seeing rising rates of colorectal cancer—the trial demonstrated exceptionally high early accuracy.

Who Is SimpleScreen™ CRC For?

SimpleScreen™ CRC is intended for adults aged 45 and older who are at average risk for colorectal cancer and receive a referral from their doctor.

However, it is important to understand where blood testing fits into your overall healthcare plan:

• It requires a doctor's referral: Your physician orders the blood draw as part of standard routine bloodwork.
• A positive result requires a colonoscopy: If SimpleScreen™ CRC flags signals of potential cancer, a follow-up colonoscopy is necessary to physically locate and evaluate the area or remove any precancerous polyps.
• Not for high-risk individuals: If you have a personal or family history of colorectal cancer, inflammatory bowel disease (IBD), or a high-risk genetic condition, colonoscopies remain the gold standard and primary screening method.

Looking Ahead: A New Standard for Routine Care

With official FDA clearance complete, Medicare coverage criteria met, and inclusion in the updated American Cancer Society screening guidelines, Abbott is rolling out SimpleScreen™ CRC across clinics and medical labs.

By turning cancer screening into something as straightforward as a routine cholesterol or diabetes blood panel, healthcare providers now have a powerful tool to catch cancer earlier—when it is most treatable—and save countless lives. If you are 45 or older and overdue for your screening, speak with your doctor to see if a simple blood test is right for you.

Sources & References

1. Freenome Inc. Press Release (July 27, 2026): "FDA Approves SimpleScreen™ CRC Blood-Based Screening Test for Colorectal Cancer; Abbott to Commercialize in the U.S."
2. Targeted Oncology / JAMA (July 28, 2026): "FDA Approves SimpleScreen Blood Test for CRC Screening: Clinical Validation in the PREEMPT CRC Trial."
3. The ASCO Post (July 29, 2026): "FDA Approves SimpleScreen CRC Blood-Based Screening Test for Colorectal Cancer."
4. American Cancer Society (ACS): Colorectal Cancer Screening Guideline Updates & Screening Rates in the U.S.